J2T-DM-KGAB - ClinicalTrials.gov - NCT04146363
J2T-DM-KGAB - ClinicalTrials.gov - NCT04146363
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must be an adult (≥18 years) or adolescent (12 to <18years) and weighing ≥40kg
Participants must have atopic dermatitis that has been present for at least one year
Participants must have ≥10% body surface area (BSA) of atopic dermatitis involvement
Participants must have had an inadequate response to treatment with topical medications and must not have had treatment with the medications dupilumab, tralokinumab or lebrikizumab
Participants must NOT
Participant must not have used certain topical atopic dermatitis treatment within 1 week
Participants must not have received a vaccine within 12 weeks of starting the study
Participants must not have hepatitis
Participants must not have a history of HIV
Participants must not have a history of cancer within 5 years
Women must not be pregnant, breastfeeding or plan to become pregnant during the study
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
400
Trial Dates
September 2019 - May 2022
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must be an adult (≥18 years) or adolescent (12 to <18years) and weighing ≥40kg
Participants must have atopic dermatitis that has been present for at least one year
Participants must have ≥10% body surface area (BSA) of atopic dermatitis involvement
Participants must have had an inadequate response to treatment with topical medications and must not have had treatment with the medications dupilumab, tralokinumab or lebrikizumab
Participants must NOT
Participant must not have used certain topical atopic dermatitis treatment within 1 week
Participants must not have received a vaccine within 12 weeks of starting the study
Participants must not have hepatitis
Participants must not have a history of HIV
Participants must not have a history of cancer within 5 years
Women must not be pregnant, breastfeeding or plan to become pregnant during the study
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
400
Trial Dates
September 2019 - May 2022
Trial Phase
3
Trial Locations
Hide locations not currently recruiting